Asarfi Hospital Ltd is Rated Buy

Apr 06 2026 10:10 AM IST
share
Share Via
Asarfi Hospital Ltd is rated Buy by MarketsMojo, with this rating last updated on 25 March 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 06 April 2026, providing investors with the most up-to-date insight into the stock’s fundamentals, returns, and overall outlook.
Asarfi Hospital Ltd is Rated Buy

Current Rating and Its Significance

MarketsMOJO’s Buy rating for Asarfi Hospital Ltd indicates a positive outlook on the stock’s potential for capital appreciation and value creation. This recommendation is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. The rating was revised on 25 March 2026, reflecting an improvement in the company’s overall mojo score from 68 to 78, signalling stronger confidence in its prospects.

Quality Assessment

As of 06 April 2026, Asarfi Hospital Ltd holds an average quality grade. This suggests that while the company maintains a stable operational foundation, there is room for improvement in areas such as operational efficiency or competitive positioning. Despite this, the company’s ability to consistently deliver positive quarterly results over the last three quarters demonstrates resilience and operational competence within the hospital sector.

Valuation Attractiveness

The valuation grade for Asarfi Hospital Ltd is classified as very attractive. Current data shows the company’s return on capital employed (ROCE) at 14.5%, paired with an enterprise value to capital employed ratio of 3. This combination indicates that the stock is trading at a favourable price relative to the capital it employs, offering investors a compelling entry point. Additionally, the company’s PEG ratio stands at a low 0.1, highlighting that earnings growth is significantly outpacing the stock price, which is a positive signal for value-conscious investors.

Financial Trend and Performance

The financial grade is outstanding, reflecting robust growth and strong profitability metrics as of 06 April 2026. The company has demonstrated a net profit growth of 29.05% and declared its highest quarterly net sales at ₹46.10 crores. Profit after tax (PAT) for the latest quarter reached ₹5.42 crores, marking a 59.5% increase compared to the previous four-quarter average. Furthermore, the company’s ROCE for the half-year period peaked at 18.55%, underscoring efficient capital utilisation. The debt to EBITDA ratio remains low at 1.96 times, indicating a strong ability to service debt and maintain financial stability.

Technical Outlook

Technically, Asarfi Hospital Ltd is mildly bullish. The stock has shown positive momentum with a 1-day gain of 1.83%, a 1-week increase of 8.58%, and a 1-month rise of 11.58%. Over the past six months, the stock has surged by 37.39%, and the one-year return stands impressively at 127.28%. This performance significantly outpaces the broader market, as the BSE500 index has recorded a negative return of -1.85% over the same period. The stock’s upward trend and relative strength suggest continued investor interest and potential for further gains.

Market Context and Shareholding

Asarfi Hospital Ltd is classified as a microcap within the hospital sector. The majority of shares are held by promoters, which often implies a stable ownership structure and alignment of interests with minority shareholders. The company’s market-beating performance, combined with its strong fundamentals and attractive valuation, positions it well for investors seeking growth opportunities in the healthcare space.

Summary for Investors

For investors, the Buy rating from MarketsMOJO signals that Asarfi Hospital Ltd currently offers a favourable risk-reward profile. The company’s strong financial trend and very attractive valuation provide a solid foundation for potential capital appreciation. While the quality grade is average, the consistent positive earnings growth and technical momentum mitigate concerns and support the stock’s appeal. Investors should consider this rating as an endorsement of the company’s current strengths and future prospects, while continuing to monitor sector dynamics and company-specific developments.

Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?

  • - Building momentum strength
  • - Investor interest growing
  • - Limited time advantage

Join the Momentum →

Performance Highlights and Outlook

The latest data as of 06 April 2026 confirms that Asarfi Hospital Ltd is delivering strong returns and operational results. The stock’s one-year return of 127.28% is a testament to its market-beating performance, especially when contrasted with the broader market’s negative returns. The company’s ability to sustain profit growth of over 29% and maintain a low leverage ratio enhances its financial robustness. These factors collectively justify the Buy rating and suggest that the stock remains an attractive proposition for investors seeking exposure to the hospital sector with growth potential.

Investor Considerations

While the Buy rating is encouraging, investors should remain mindful of the company’s average quality grade, which may reflect operational or competitive challenges that could impact long-term sustainability. Additionally, as a microcap, the stock may exhibit higher volatility and liquidity considerations. Nonetheless, the strong financial trend and attractive valuation provide a cushion against such risks. Investors are advised to consider their risk tolerance and investment horizon when evaluating this stock.

Conclusion

In summary, Asarfi Hospital Ltd’s current Buy rating by MarketsMOJO, updated on 25 March 2026, is supported by compelling financial metrics and positive technical signals as of 06 April 2026. The company’s very attractive valuation, outstanding financial trend, and mild technical bullishness make it a noteworthy candidate for investors seeking growth in the healthcare sector. The average quality grade suggests some caution, but the overall outlook remains favourable.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News